跳至主要内容
临床试验/NCT04150731
NCT04150731已完成1 期

16α-18F-fluor-17β-østradiol PET/CT Til Visualisering af østrogenreceptor-positive Levermetastaser Fra brystkræft

University of Aarhus2 个研究点 分布在 1 个国家目标入组 8 人开始时间: 2020年10月23日最近更新:
适应症

试验速览

阶段
1 期
状态
已完成
入组人数
8
试验地点
2
主要终点
Sensitivity of parametric FES-PET/CT

研究概览

简要总结

Breast cancer (BC) is the most common cancer diagnosis among women and the incidence is increasing. Prognosis and treatment are dependent on the expression of estrogen receptors (ER) in the tumor. ER status is determined by immunohistochemistry (IHC) on biopsy tissue. The ER expression can change over time and be heterogeneous.

The IHC score on ER expression is subjective and can lead to intra and inter observer variability. A new computer image analysis software that can give the exact percentage of colored tumor cells on sectional tumor cuts has been developed.

It is also possible to quantify the ER expression non invasive by using the tracer 16α-18F-flour-17β-estradiol (FES) and in vivo positron emission tomography (PET) scans. FES-PET/CT has a high background activity in the liver which complicates the visualization of liver metastases. Theoretically, a new whole body parametric scan method makes it possible to distinguish background activity from uptake in liver metastases.

Malignant tumors often have an increased perfusion, and previous studies have found that tumors with low metabolism relative to blood flow have the longest disease free survival (DFS). To the best of our knowledge, no previous studies have examined the correlation between ER expression and blood flow.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Diagnostic
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patients with known disseminated breast cancer
  • Metastatic ER+ HER2- breast cancer with metastases in the liver, at least two separate liver foci visualised on CT
  • Diagnostic CT scan done in connection with clinical control
  • Treatment with aromatase inhibitors, and potential additional treatment
  • Postmenopausal

排除标准

  • Treatment with Tamoxifen or Fulvestrant completed within 5 weeks prior to FES-PET/CT
  • ER- metastases
  • Life expectancy under three months
  • Claustrophobia
  • Any pain which makes it impossible to lie in the scanner for 90 minutes

结局指标

主要结局

Sensitivity of parametric FES-PET/CT

时间窗: 1 year

Examine the sensitivity of parametric FES-PET/CT compared to conventional FES-PET/CT to detect estrogen receptor (ER) positive liver metastases

次要结局

  • Examination of the heterogeneity of ER expression in liver metastases(1 year)
  • Correlation of tumor blood flow to ER+ cells(1 year)
  • Correlation of ER expression(1 year)
  • Examination of the heterogeneity of ER expression i metastases(1 year)
  • Examination of the heterogeneity of ER expression(1 year)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验